Marino Stram & Associates LLC Buys 20 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Marino Stram & Associates LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 396 shares of the biopharmaceutical company’s stock after buying an additional 20 shares during the quarter. Marino Stram & Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $208,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Kingswood Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 19 shares during the period. Creative Financial Designs Inc. ADV boosted its position in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 19 shares in the last quarter. Private Trust Co. NA boosted its position in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 19 shares in the last quarter. Proficio Capital Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 19 shares during the period. Finally, Cove Private Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.5% in the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.3%

Shares of REGN opened at $562.27 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,061.60. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $570.12 and its two-hundred day moving average is $568.72. The stock has a market cap of $59.59 billion, a PE ratio of 14.17, a price-to-earnings-growth ratio of 1.79 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.56 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Analysts Set New Price Targets

A number of research analysts have weighed in on REGN shares. Citigroup reaffirmed a “buy” rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Sanford C. Bernstein raised their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Canaccord Genuity Group restated a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research report on Monday, August 4th. Finally, Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.